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ABSTRACT
Background Colorectal adenomatous polyposis is
associated with a high risk of colorectal cancer (CRC)
and is frequently caused by germline mutations in APC
or MUTYH. However, in about 20–30% of patients no
underlying gene defect can be identified. In this study,
we tested if recently identified CRC risk variants play a
role in patients with >10 adenomas.
Methods We analysed a total of 16 SNPs with a
reported association with CRC in a cohort of 252
genetically unexplained index patients with >10
colorectal adenomas and 745 controls. In addition, we
collected detailed clinical information from index patients
and their first-degree relatives (FDRs).
Results We found a statistically significant association
with two of the variants tested: rs3802842 (at
chromosome 11q23, OR=1.60, 95% CI 1.3 to 2.0) and
rs4779584 (at chromosome 15q13, OR=1.50, 95% CI
1.2 to 1.9). The majority of index patients (84%) had
between 10 and 100 adenomas and 15% had >100
adenomas. Only two index patients (1%), both with
>100 adenomas, had FDRs with polyposis. Forty-one
per cent of the index patients had one or more FDRs
with CRC.
Conclusions These SNPs are the first common, low-
penetrant variants reported to be associated with
adenomatous polyposis not caused by a defect in the
APC, MUTYH, POLD1 and POLE genes. Even though
familial occurrence of polyposis was very rare, CRC was
over-represented in FDRs of polyposis patients and, if
confirmed, these relatives will therefore benefit from
surveillance.
INTRODUCTION
Adenomatous polyps are the primary precursor
lesions of colorectal cancer (CRC).1 Patients with
large numbers of adenomas (polyposis) have a high
likelihood of carrying an inheritable high-
penetrance germline defect, particularly those
patients diagnosed at a young age. Germline muta-
tions in APC and MUTYH are commonly found in
patients with an adenomatous polyposis phenotype.
More recently, mutations in the POLD1 and POLE
genes were also shown to be a cause of polyposis.2
Nevertheless, a substantial number (ie, an estimated
20–30%, also depending on polyp count and age at
diagnosis) of patients remain unexplained. Some
susceptibility of these unexplained cases may be
attributable to the SNPs that are known to increase
CRC risk (table 1). Eight of these SNPs were
recently shown to be over-represented in CRC-free
patients with few (mean=2) adenomatous polyps.3
The main aim of our study was to investigate
whether CRC-risk SNPs are associated with disease
in patients with more than 10 colorectal adenomas
but without a known causative mutation, that is, no
germline mutations in the APC, MUTYH, POLD1
and POLE genes. In addition, the phenotype in




Patients were genotyped in a consecutive series of
1216 index patients tested for APC and/or
MUTYH germline mutations at the Laboratory for
Diagnostic Genome Analysis (LDGA) in Leiden,
from 1986 to January 2009. Informed consent was
given for further research at initial blood with-
drawal. Exclusion criteria were less than 10 aden-
omas, low-quality DNA samples, a phenotype with
predominantly hyperplastic polyposis or missing
clinical information on the histopathology of the
polyps.
Clinical data were collected from the
Netherlands Foundation for the Detection of
Hereditary Tumors (NFDHT) and from clinical
genetics departments in the Netherlands. Collected
data included date of birth, gender, date of diagno-
sis of polyposis, cumulative number of polyps
counted at colonoscopy or in excised bowel, loca-
tion and histology of polyps, presence of duodenal
polyps, information on CRC, polyps/CRC in first-
degree family members, date of last contact and
status at last contact. The control cohort was
described previously4 and comprised a total of 745
controls for which both gender and age at blood
sampling was known were included.
Genotyping
The APC and MUTYH genes had been tested as
published previously.5 6 Hotspot mutations for
POLE (p.L424V) and POLD1 (p.S478N) were
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determined for all cases using an in-house developed KASPar
assay (primers available upon request). Next, those cases
without APC, MUTYH or the POLD1 or POLE hotspot muta-
tions were selected for genotyping the 16 SNPs listed in table 1.
Anonymised samples of leucocyte DNA from these cases and
controls were tested using the Competitive Allele-Specific PCR
(KASPar) assay as described previously.7 All KASPar genotyping
assays were performed by KBiosciences, UK.
Statistical analysis
All statistical analyses were carried out using PLINK,8 including
calculations of allele differences between cases and controls,
genotype call rate per sample and per SNP, deviations from
Hardy–Weinberg equilibrium (HWE), as well as multiple test
correction. Genotypes of cases and controls were compared
using a basic χ2 allelic test. SNP profiles of specific subcohorts
are available upon request. Multiple test correction was done
using false discovery rate estimation.9
RESULTS
Genotype
Of the 1216 index patients surveyed, 252 patients fulfilled our
inclusion criteria for SNP genotyping. We analysed 16 SNPs and
compared allele frequencies in our mutation-negative cohort
and in the control population (table 1). The call rates were
above 99%. No deviations from HWE were observed. The asso-
ciation was strongest for SNPs rs3802842 (p=2.0×10−5;
OR=1.60, 95% CI 1.3 to 2.0) and rs4779584 (p=0.001;
OR=1.50, 95% CI 1.2 to 1.9) that remained significant after
adjustment for multiple testing (p=0.001 and 0.026,
respectively).
In order to disentangle whether the identified association for
these two SNPs was based on polyposis or CRC, we compared
allele frequencies in index patients with (n=96) and without
CRC (n=156) and in our control population. The association
for SNPs rs3802842 (p=0.0037; OR=1.5 (95% CI 1.1 to 1.9))
and rs4779584 (p=0.023; OR=1.4 (95% CI 1.0 to 1.9))
remained statistically significant for patients without CRC, that
is, with a polyposis-only phenotype. In addition, the 14 other
SNPs were not significantly associated with CRC.
Phenotype
The clinical description of the 252 patients is listed in table 2.
The majority of cases (63%) had a cumulative polyp count of
between 10 and 50 (with a mean age at diagnosis of 53 years),
21% showed between 50 and 100 polyps, while 15% of the cases
had more than 100 polyps (‘carpeted’, ‘numerous’, ‘classic polyp-
osis’ definitions included). Histopathologic examination showed
all or a vast majority of polyps as adenomas in 208 cases (83%),
while 44 cases (17%) displayed a mixed phenotype of predomin-
antly adenomas with some hyperplastic polyps. Our cohort
included 64 patients that carried both SNPs. These patients did
not appear to have a more exacerbated phenotype (ie, 41/160
(26%) in the 10–50 group, 10/53 (19%) in the 50–100 group and
13/39 (33%) in the >100 polyp count group).
CRC was found in 96 patients (38%) at a mean age of
53 years. A substantial number of patients (17%) had two or
more synchronous or metachronous CRCs (n=16), and three
(n=1) or even four (n=1) synchronous CRCs were also seen. In
terms of location, 48 CRCs were found distal to the splenic
flexure (left-sided CRC), 23 CRCs were right sided and 9
patients had both left-sided and right-sided tumours. The exact
tumour location was unknown for 16 CRCs. A total of 81
patients (32%) underwent upper gastrointestinal endoscopy.
Fifteen patients (19%) had duodenal adenomas, and one patient
had both duodenal and gastric polyps.
On investigation of family history, 143 (57%) index patients
had close relatives with colorectal tumours; 104 patients (41%)
had one or more FDRs with CRC, diagnosed at a mean age of
60 years (table 2). A steep increase in CRC incidence for FDRs
was observed after the age of 30 (figure 1). Moreover, 103
patients (41%) had one or more FDRs with polyps. A family
history with strong phenotypes was present in only two families,
and in addition to index patients with >100 adenomas, one
Table 1 Summary results for the tested SNPs in 252 patients with unexplained adenomatous polyposis and 745 healthy controls
Allele* MAF
Chr SNP Base-pair position† Minor Major Patients Controls p Value OR (95% CI) Gene Reference
1q41 rs6691170 222045446 T G 0.378 0.346 0.194 1.1 (0.9-1.4) DUSP10 CICP13 32
1q41 rs6687758 222164948 G A 0.228 0.197 0.141 1.2 (0.9 to 1.5) DUSP10 CICP14 32
3q26.2 rs10936599 169492101 T C 0.237 0.244 0.745 1.0 (0.8 to 1.2) MYNN 32
8q23.3 rs16892766 117630683 C A 0.086 0.086 0.998 1.0 (0.7 to 1.4) TRPS1 EIF3H 33
8q24.21 rs6983267 128413305 G T 0.575 0.530 0.078 1.2 (1.0 to 1.5) POU5F1 MYC 34
10p14 rs10795668 8701219 A G 0.290 0.324 0.154 0.9 (0.7 to 1.1) KRT8P16 TCEB1P3 33
11q23 rs3802842 111171709 C A 0.355 0.256 0.00002 1.6 (1.3 to 2.0) C11orf93 11
12q13.13 rs7136702 50880216 T C 0.357 0.327 0.222 1.1 (0.9 to 1.4) TBX3 UBA52P7 32
12q13.13 rs11169552 51155663 T C 0.260 0.264 0.876 1.0 (0.8 to 1.2) DIP2B ATF1 32
14q22.2 rs4444235 54410919 C T 0.444 0.437 0.763 1.0 (0.8 to 1.3) RPS3AP46 BMP4 12
15q13 rs4779584 32994756 T C 0.256 0.187 0.001 1.5 (1.2 to 1.9) SCG5 GREM1
FMN1 CRAC1
35
16q22.1 rs9929218 68820946 A G 0.280 0.278 0.921 1.0 (0.8 to 1.3) CDH1 12
18q21.1 rs4939827 46453463 C T 0.486 0.491 0.864 1.0 (0.8 to 1.2) SMAD7 14
19q13.1 rs10411210 33532300 T C 0.090 0.092 0.918 1.0 (0.7 to 1.4) RHPN2 12
20p12.3 rs961253 6404281 A C 0.386 0.375 0.661 1.0 (0.9 to 1.3) TARDBPL BMP2 12
20q13.33 rs4925386 60921044 T C 0.297 0.316 0.423 0.9 (0.7 to 1.1) LAMA5 32
*For SNP rs6983267, the minor allele originally reported (G) is the most frequent allele, both in our cases and controls.
†The SNP positions are according to Human Build 36.3.
Chr, chromosome; MAF, minor allele frequency.
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sister had >50 adenomas and the brother of the second case
had >100 adenomas. The remaining index patients all had
FDRs with low polyp counts (ie, less than 10 adenomas).
DISCUSSION
The present study provides new susceptibility loci for patients
with colorectal adenomatous polyposis, defined here as a
Figure 1 Age distribution as kernel
density estimates. Age of controls at
blood withdrawal, age of index
patients at polyposis diagnosis (Polyps)
and age of index patients at colorectal
cancer (CRC) diagnosis. The lower part
shows the age of diagnosis of polyps
and CRC in first-degree relatives
(FDRs).
Table 2 Clinical details of three categories of index patients: 10–50 adenomas, 50–100 adenomas and >100 adenomas
Panel A
Index Personal history
Adenomas (n) Number Mean age Men (%) CRC Men (%) Age at CRC
Duodenal
adenoma
10–50 160 63% 53 (29–82) 63 59 37% 56 53 (26–75) 7/20 35%
50–100 53 21% 51 (13–73) 57 18 34% 72 55 (37–73) 1/17 6%
>100 39 15% 44 (4–80) 56 19 49% 58 51 (29–80) 7/44 16%
Total 252 100% 51 (4–82) 60 96 38% 59 53 (26–80) 15/81 19%
Panel B
Family history
Adenomas (n) FH FDRs with CRC (n) Age at CRC FDRs with polyps (n) Age
10–50 95 59% 72 61 (32–85) 68 55 (30–85)
50–100 30 57% 20 62 (44–91) 21 55 (26–78)
>100 18 46% 12 56 (17–79) 14 51 (15–70)
Total 143 57% 104 60 (17–91) 103 55 (15–85)
Panel A: Clinical details of the index patients. Number of patients, percentage and mean age at diagnosis; number and percentage of male patients; number, percentage, sex
distribution and age at diagnosis of CRC in polyposis patients; number of patients with duodenal adenomas/patients who underwent upper gastrointestinal endoscopy.
Panel B: Clinical data of the first-degree relatives (FDRs) of the index patients. Number and percentage of index patients with a positive family history (FH), that is, FDRs with CRC and/
or multiple adenomas (ie, <10 polyps).
CRC, colorectal cancer.
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cumulative total of more than 10 colorectal adenomas, without
an identified causative germline defect. Variants rs3802842 (on
chromosome 11q23.1) and rs4779584 (on chromosome 15q13)
are the first common, low-penetrant risk variants reported in
this type of patients. The ORs we found (1.60 and 1.50) are
much higher than values reported for patients with a few
adenomas or for patients with CRC (typically ORs of 1.1
to 1.2).3 10–12 Our series is biased towards ascertaining index
patients and their family members presenting with symptomatic
CRC and is not a population-based series of polyposis patients.
Therefore, prospective studies are needed to confirm our
findings. Moreover, disentanglement of whether the identified
association for these two SNPs was based on polyposis or CRC
is difficult given how much these two phenotypes are interre-
lated. However, we found that the association still stood in the
index patients with a polyposis-only phenotype, that is, after
excluding the index patients with CRC. Therefore, even though
the low-risk variants identified in the present study are unlikely
to explain polyposis by themselves, they still might act as modi-
fiers of so far unidentified high-risk factors or participate in a
multifactorial cause of the phenotype.
The SNP rs3802842 appears to be involved in risk predispos-
ition in hereditary forms of CRC and has previously been asso-
ciated with early-onset CRC (diagnosed under the age of
50 years), low numbers of adenomas and familial aggregation of
CRC.4 13 14 Moreover, rs3802842 was also shown to be associated
with CRC risk in female patients with Lynch syndrome.15 16
Mechanistically, none of the transcripts (FLJ45803, LOC120376,
C11orf53 and POU2AF1) mapping to the rs3802842 region at
chromosome 11q23 showed possible causative exonic mutations,
and rs3802842 is currently annotated to an intron of an uncharac-
terised protein, C11orf93. While the impact of this SNP might be
via non-coding effects on gene expression, a clear mechanistic
explanation for this association remains elusive despite extensive
research.17
A more plausible mechanistic explanation may be available
for the SNP rs4779584, as its chromosome 15q13.3 locus
encompasses the genes SCG5, FMN1 and GREM1. A 40 kb
duplication upstream of the GREM1 gene was previously identi-
fied in a large Ashkenazi family with a mixed polyposis pheno-
type.18 GREM1 is a component of the TGF-b superfamily
signalling pathway acting as a bone morphogenetic protein
(BMP) antagonist in the colon. Increased GREM1 expression is
predicted to reduce BMP activity, a mechanism also found in
juvenile polyposis.18 Given the reported association of 15q13
SNP with a mixed polyposis phenotype, we compared the
allelic counts in patients with adenoma and patients with a
phenotype of predominantly adenomas and some hyperplastic
polyps (table 3). However, we did not find an over-
representation of the 15q13 SNP in the subset with both aden-
omas and hyperplastic polyps (p=0.5).
Phenotype
In our large cohort of patients with genetically unexplained
polyposis, medical records were scrutinised in order to collect
accurate phenotypic data. The majority of subjects exert a
phenotype resembling that of attenuated adenomatous polyposis
since they had a moderate number of polyps (ranging from 10
to 100) at an advanced age of diagnosis (mean age 52 years).
The proportion of patients affected with duodenal adenomas
was also in more agreement with MUTYH- (ie, 20%) than
classic APC-associated polyposis (ie, 90%).19 20 Previous studies
on APC and MUTYH mutation-negative polyposis patients show
a clinically heterogeneous disease, with scarce information on
family members.21–30
Regarding family history, strong phenotypes (>50 adenomas)
were present in only two families (1%), and 41% of the index
patients had one or more FDRs with single or multiple aden-
omas (ie, <10 polyps). Moreover, CRC in FDRs was observed
in 41% of the index patients. This observation mimics studies
on hyperplastic polyposis, where even in the absence of hyper-
plastic polyposis an increased CRC risk for FDRs of patients
was found and for whom surveillance is advised.23 31
Clinical implications
Based on the clinical evaluation of our cohort, the following
surveillance guidelines for FDRs of polyposis patients without
known cause may be considered. First, to exclude the presence
of polyposis—and despite the rare occurrence in the relatives of
the patients in our series—we would recommend performing
colonoscopy in parents, siblings and offspring at an early age.
Based on the endoscopic findings, decisions can be made on the
need for follow-up examinations. Second, based on the high
CRC incidence in FDRs, we would also recommend colono-
scopic surveillance, even in the absence of a polyposis pheno-
type on first colonoscopy at an early age. Given the age
distribution of CRC onset in FDRs (figure 1), we suggest that
surveillance commence at age 30, with intervals of 5–6 years
dependent on endoscopic findings.
In conclusion, this is the first study to report an association
between common, low-penetrance genetic variants and an unex-
plained adenomatous polyposis phenotype. Future studies
should explore the mechanistic role of these variants in the
development of polyposis. Whereas the familial occurrence of
polyposis in relatives was rare, almost half of FDRs developed
CRC. If over-representation of CRC in FDRs of polyposis
patients is confirmed in other studies, these relatives should
undergo colonoscopic surveillance, even in the absence of a
polyposis phenotype upon first colonoscopy.
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